×
About 52,473 results

Lung Screening Saves Lives; Clues to Hyperprogression; Bacteria Foil Immunotherapy
https://www.medpagetoday.com/hematologyoncology/lungcancer/101912

Nov 25th, 2022 - Diagnosis of early-stage lung cancer with low-dose CT screening was associated with significant improvement in long-term survival. (Mount Sinai, Radiological Society of North America) Researchers have discovered how cancer immunotherapy sometimes causes paradoxical tumor hyperprogression and identified a potential mechanism to prevent it. (Science Translational Medicine) Continuing its expansio...

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
https://doi.org/10.1007/s11899-022-00682-4
Current Hematologic Malignancy Reports; McCurdy A, Visram A

Nov 24th, 2022 - Multiple myeloma (MM) is a hematologic malignancy of plasma cells that remains incurable with currently available therapies including proteosome inhibitors, immunomodulators, monoclonal antibodies, corticosteroids, and alkylators, in addition to autologous stem cell transplantation in patients who are eligible. Novel therapeutics are therefore required to improve patient outcomes. The goal of t...

Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the t...
https://doi.org/10.1080/10428194.2022.2148214
Leukemia & Lymphoma; Kumar L, Sahoo RK et. al.

Nov 24th, 2022 - We evaluated impact of melphalan dose on transplant outcomes for multiple myeloma. Between 1995 and 2019 459 consecutive patients received a transplant; 69(15%) received melphalan ≤150 mg/m2 (Mel 150 cohort) and 390 (85%) melphalan 200 mg/m2 (MEL 200 cohort). The primary outcome was overall survival (OS) from the date of transplant. Progression-free survival (PFS), engraftment, transplant respo...

Vax Conspiracy Film Hits Twitter; More Apnea Device Deaths; GSK Pulls Cancer Drug
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/101895

Nov 23rd, 2022 - Note that some links may require subscriptions. Also note that Morning Break will be taking its own break Thursday and Friday for the Thanksgiving holiday. Look for it again on Monday, November 28. The anti-vax film "Died Suddenly," which claims COVID vaccines were designed to depopulate the world, premiered on Twitter. (Forbes) Pediatric hospitalizations spiked up to 60% on Long Island as resp...

NK cell therapy in relapsed refractory multiple myeloma.
https://doi.org/10.1016/j.clim.2022.109168
Clinical Immunology (Orlando, Fla.); Roshandel E, Ghaffari-Nazari H et. al.

Nov 23rd, 2022 - Recent advances in adoptive cell therapy have considerably changed the paradigm of cancer immunotherapy. Although current immunotherapies could cure many patients with multiple myeloma (MM), relapsed/refractory MM (RR/MM) is still challenging in some cases. Natural killer (NK) cells are innate immune cells that exert effective cytotoxic activity against malignant cells like myeloma cells. In ad...

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated ...
https://doi.org/10.1200/JCO.21.02734
Journal of Clinical Oncology : Official Journal of the Am... Sonneveld P, Chanan-Khan A et. al.

Nov 23rd, 2022 - At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). CASTOR was a multicenter, randomize...

Geographical and ecological analyses of multiple myeloma in Denmark: Identification of ...
https://doi.org/10.1111/ejh.13904
European Journal of Haematology; Bertelsen LD, Børty Nielsen L et. al.

Nov 23rd, 2022 - The aetiology of multiple myeloma (MM) is unknown but various environmental exposures are suspected as risk factors. We present the first paper analysing the geographical distribution of MM in Denmark at municipal level to investigate variation that could be explained by environmental exposures. Patients diagnosed with MM in Denmark during 2005-2020 were identified from nationwide registries an...

Sarcopenia identified by computed tomography imaging using a deep learning-based segmen...
https://doi.org/10.1002/cncr.34545
Cancer Nandakumar B, Baffour F et. al.

Nov 23rd, 2022 - Sarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning-based segmentation approach, clinical computed tomography (CT) images of the abdomen of patients with newly diagnosed multiple myeloma (NDMM) were reviewed to determine whether the presence of sarcopenia had any prognostic value. Sarcopenia was detected by accurate segme...

Open-Label, Pilot Study of Romiplostim for Thrombocytopenia After Autologous Hematopoie...
https://doi.org/10.1182/bloodadvances.2022007838
Blood Advances; Scordo M, Gilbert LJ et. al.

Nov 22nd, 2022 - There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen-induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (autoHCT). We conducted an open-label, single-arm pilot study of romiplostim, a thrombopoietin receptor agonist, to enhance platelet recovery in patients with multiple myeloma or lymphoma undergoing autoHCT. Al...

Peripheral Blood Monocyte Count is a Dynamic Prognostic Biomarker in Multiple Myeloma.
https://doi.org/10.1182/bloodadvances.2022008021
Blood Advances; Edwards CV, Hassan H et. al.

Nov 22nd, 2022 - With growing knowledge of multiple myeloma (MM) pathobiology and the introduction of novel therapies, risk stratification continues to evolve. Myeloid-derived suppressor cells and tumor-associated macrophages, derived from peripheral blood monocytes, support malignant plasma cell proliferation in the bone marrow. Since peripheral blood absolute monocyte count (AMC) is thought to could reflect t...

Treatment patterns and overall survival of patients with double-class and triple-class ...
https://doi.org/10.1080/10428194.2022.2140284
Leukemia & Lymphoma; Wang PF, Yee CW et. al.

Nov 22nd, 2022 - Patients with relapsed/refractory multiple myeloma (RRMM) resistant to multiple drug classes remain a high unmet need population. This longitudinal retrospective cohort study assessed real-world treatment patterns and outcomes in adults with RRMM. Patients who had three or more prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (double-exposed) were furth...

Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for...
https://doi.org/10.1016/j.clml.2022.09.001
Clinical Lymphoma, Myeloma & Leukemia; Martin T, Jackson CC et. al.

Nov 22nd, 2022 - Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized the treatment paradigm for heavily pretreated B-cell malignancies such as large B-cell lymphoma. There is a major unmet need for effective treatments for heavily pretreated relapsed/refractory multiple myeloma (RRMM), for which many CAR-T therapies are under active clinical investigation. Goal of the review: This review prov...

Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditio...
https://doi.org/10.1016/j.clml.2022.10.004
Clinical Lymphoma, Myeloma & Leukemia; Khan AM, Yucebay F et. al.

Nov 22nd, 2022 - High-dose melphalan (HDM) with autologous hematopoietic cell transplantation (AHCT) after induction chemotherapy is considered standard of care in transplant-eligible patients with newly-diagnosed multiple myeloma (MM). Alkeran melphalan has propylene glycol as a solvent (PG-mel) while Evomela utilizes a propylene glyclol-free formulation (PGF-mel). We evaluated the differences in efficacy and ...

Blenrep for Multiple Myeloma Withdrawn From US Market
https://www.medscape.com/viewarticle/984437

Nov 22nd, 2022 - A drug used in the treatment of relapsed/refractory multiple myeloma (RRMM) is in the process of being pulled off the US market by its manufacturer. The drug is belantamab mafodotin-blmf (Blenrep), an antibody drug conjugate that targets B-cell maturation antigen (BCMA). The manufacturer, GSK, announced that it has started the process of withdrawing this drug from the market at the request of t...

Utility of CD229 as novel marker in measurable residual disease assessment in multiple ...
https://doi.org/10.1111/ijlh.13992
International Journal of Laboratory Hematology; Rai S, Das N et. al.

Nov 21st, 2022 - CD229 has been found to be a useful plasma cell (PC) gating marker in multiple myeloma (MM). This study analyses the expression profile of CD229 on various bone marrow compartments namely, PC, non-PC and hematogones (HGs) using Multiparameter flow cytometry (MFC). Furthermore, it evaluates the ability of CD229 to delineate normal PC (NPC) from aberrant PC (APC) in measurable residual disease as...

Geriatric assessment in hematology scale predicts treatment tolerability in older patie...
https://doi.org/10.1016/j.jgo.2022.10.016
Journal of Geriatric Oncology; de la Rubia J, González B et. al.

Nov 21st, 2022 - The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weight...

Validation of the revised diagnostic criteria for primary plasma cell leukemia by the K...
https://doi.org/10.1038/s41408-022-00755-w
Blood Cancer Journal; Jung SH, Kim K et. al.

Nov 21st, 2022 - The International Myeloma Working Group has recently revised the diagnostic criteria for primary plasma cell leukemia (PCL) to circulating plasma cells (CPCs) ≥ 5% in a peripheral blood smear. The present study validated new criteria in patients with multiple myeloma or PCL diagnosed using the previous diagnostic criteria, who were administered immunomodulatory drugs or proteasome inhibitors as...

Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunolog...
https://doi.org/10.1016/j.clml.2022.10.009
Clinical Lymphoma, Myeloma & Leukemia; Ojo AS, Akinyemi O et. al.

Nov 20th, 2022 - A subset of individuals with smoldering myeloma (SMM) are at a high risk of progression to symptomatic myeloma. Current efforts are focused on identifying this high-risk group and intercepting the disease process before its progression. There is no consensus on what the goal of an intervention should be, whether to aim for a cure through a high-intensity intervention or pursue immunologic disea...

Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chine...
https://doi.org/10.1016/j.clml.2022.10.007
Clinical Lymphoma, Myeloma & Leukemia; Fu W, Li W et. al.

Nov 20th, 2022 - In the phase 3 LEPUS study, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Here, we report updated efficacy and safety results from LEPUS. Chinese patients with ≥ 1 prior line of therapy were randomized 2:1 to bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for ...

Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomer...
https://doi.org/10.1177/09603271221124094
Human & Experimental Toxicology; Wang L, Yin H et. al.

Nov 20th, 2022 - Bortezomib (BTZ) is a first-generation proteasome inhibitor with anti-tumor properties for multiple myeloma and mantle cell lymphoma. Increasing evidence has shown that BTZ exhibits toxic effects on diverse tumor cells, including non-small cell lung cancer (NSCLC) cells. However, the mechanism has not been fully evaluated. Here, we examined the regulatory effect of BTZ on cellular senescence, a...